Some of the successful biologicals used in RA are cytokine blockers, including reagents targeting TNF (beginning with etanercept and infliximab) [10] and the inhibitory antibody tocilizumab, which targets the IL-6R [11]. The gene discussed is TNF; the disease is rheumatoid arthritis.